Compare NMTC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | IMRN |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.7M |
| IPO Year | 2010 | 2016 |
| Metric | NMTC | IMRN |
|---|---|---|
| Price | $0.76 | $0.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.27 | N/A |
| AVG Volume (30 Days) | ★ 55.4K | 16.1K |
| Earning Date | 12-16-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,097,692.00 | N/A |
| Revenue This Year | N/A | $12.00 |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.47 | N/A |
| 52 Week Low | $0.61 | $0.68 |
| 52 Week High | $12.24 | $1.99 |
| Indicator | NMTC | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 45.21 |
| Support Level | $0.77 | $0.90 |
| Resistance Level | $1.35 | $1.00 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 18.07 | 69.89 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.